Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review

[1]  W. Bemelman,et al.  Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease—an International, Cross-disciplinary Consensus , 2018, Journal of Crohn's & colitis.

[2]  D. Hommes,et al.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial , 2017, The Lancet.

[3]  D. Jonkers,et al.  Patient‐Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  S. Schreiber,et al.  Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study , 2017, Gut.

[5]  Fengbin Liu,et al.  Inflammatory bowel disease-specific health-related quality of life instruments: a systematic review of measurement properties , 2017, Health and Quality of Life Outcomes.

[6]  J. Fidler,et al.  Endoscopic and Radiographic Assessment of Crohn's Disease. , 2017, Gastroenterology clinics of North America.

[7]  G. D'Haens,et al.  Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  G. Van Assche,et al.  Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  P. Rutgeerts,et al.  Eldelumab [anti-interferon-&ggr;-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study , 2017, Journal of Crohn's & colitis.

[10]  K. Patra,et al.  Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. , 2017, Gastroenterology.

[11]  W. Sandborn,et al.  Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey , 2017, BMJ Open.

[12]  A. Kaser,et al.  Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study , 2017, The Lancet.

[13]  S. Vermeire,et al.  Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials , 2017, Gut.

[14]  S. Travis,et al.  Evolving Concepts in Phases I and II Drug Development for Crohn’s Disease , 2017, Journal of Crohn's & colitis.

[15]  S. Vermeire,et al.  OP035 Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease. , 2017, Journal of Crohn's & colitis.

[16]  S. Schreiber,et al.  Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial , 2017, The Lancet.

[17]  P. Rutgeerts,et al.  Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease , 2017, The American Journal of Gastroenterology.

[18]  D. Hommes,et al.  Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  M. Ferrante,et al.  Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial , 2016, The Lancet.

[20]  R. Prescott,et al.  Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial , 2016, The lancet. Gastroenterology & hepatology.

[21]  G. D'Haens,et al.  Histologic scoring indices for evaluation of disease activity in Crohn's disease. , 2016, The Cochrane database of systematic reviews.

[22]  S. Targan,et al.  A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease , 2016, The American Journal of Gastroenterology.

[23]  S. Vermeire,et al.  Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease , 2015, Alimentary pharmacology & therapeutics.

[24]  M. Braddock,et al.  Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study , 2015, Inflammatory bowel diseases.

[25]  S. Vermeire,et al.  IOIBD technical review on endoscopic indices for Crohn's disease clinical trials , 2015, Gut.

[26]  T. Murdoch,et al.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.

[27]  W. Sandborn,et al.  C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis , 2015, The American Journal of Gastroenterology.

[28]  P. Rutgeerts,et al.  Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease , 2015, Gut.

[29]  S. Hanauer,et al.  Briakinumab for Treatment of Crohn's Disease: Results of a Randomized Trial , 2015, Inflammatory bowel diseases.

[30]  A. Sakov,et al.  A phase II study of laquinimod in Crohn's disease , 2014, Gut.

[31]  W. Sandborn,et al.  A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  P. Rutgeerts,et al.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.

[33]  L. Peyrin-Biroulet,et al.  Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  J. Fletcher,et al.  EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging , 2013, The American Journal of Gastroenterology.

[35]  M. Sans,et al.  Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. , 2013, Gastroenterology.

[36]  P. Rutgeerts,et al.  Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial , 2013, Gut.

[37]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[38]  T. Hibi,et al.  Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study. , 2013, Journal of Crohn's & colitis.

[39]  S. Vermeire,et al.  A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease , 2013, PloS one.

[40]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[41]  Jane M Blazeby,et al.  Developing core outcome sets for clinical trials: issues to consider , 2012, Trials.

[42]  Marc Vandemeulebroecke,et al.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.

[43]  P. Rutgeerts,et al.  Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. , 2012, Gastroenterology.

[44]  T. Hibi,et al.  Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. , 2012, Journal of Crohn's & colitis.

[45]  P. Rutgeerts,et al.  Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[46]  J. Gisbert,et al.  Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[47]  W. Sandborn,et al.  Phase 2 Randomized Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Crohn's Disease , 2011 .

[48]  P. Rutgeerts,et al.  Phase I, double‐blind, randomized, placebo‐controlled, dose‐escalation study of NI‐0401 (a fully human anti‐CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease† , 2010, Inflammatory bowel diseases.

[49]  S. Hanauer,et al.  Briakinumab (Anti-interleukin 12/23p40, ABT874) for Treatment of Crohnʼs Disease (CD): 1245 , 2010 .

[50]  B. Sands,et al.  Randomized, double‐blind, placebo‐controlled trial of the oral interleukin‐12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease , 2010, Inflammatory bowel diseases.

[51]  P. Rutgeerts,et al.  A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease , 2010, Gut.

[52]  P. Rutgeerts,et al.  Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study , 2010, Inflammatory bowel diseases.

[53]  T. Humphries,et al.  Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 study , 2009, Gut.

[54]  T. Hibi,et al.  S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial , 2009 .

[55]  S. Hanauer,et al.  Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study , 2009, BMC gastroenterology.

[56]  M. Regueiro,et al.  Infliximab prevents Crohn's disease recurrence after ileal resection. , 2009, Gastroenterology.

[57]  A. Cohen,et al.  Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[58]  P. Rutgeerts,et al.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. , 2008, Gastroenterology.

[59]  S. Schreiber,et al.  A Multicenter, Randomized, Double-Blind Trial of Everolimus Versus Azathioprine and Placebo to Maintain Steroid-Induced Remission in Patients With Moderate-to-Severe Active Crohn's Disease , 2008, The American Journal of Gastroenterology.

[60]  A. Forbes,et al.  A randomized, double‐blind, placebo‐controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease , 2007, Alimentary pharmacology & therapeutics.

[61]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[62]  S. Schreiber,et al.  Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.

[63]  S. Hanauer,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.

[64]  S. Targan,et al.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.

[65]  S. Hanauer,et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.

[66]  W. Chey,et al.  A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[67]  P. Rutgeerts,et al.  Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[68]  J. Mary,et al.  Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.

[69]  G. Radford-Smith,et al.  CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial , 2006, Alimentary pharmacology & therapeutics.

[70]  S. Schreiber,et al.  Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[71]  D. Hommes,et al.  Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease , 2006, Gut.

[72]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[73]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[74]  P. Rutgeerts,et al.  A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease , 2005, Gut.

[75]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.

[76]  R. Modigliani,et al.  A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. , 2005, Gastroenterology.

[77]  J. Korzenik,et al.  Sargramostim for active Crohn's disease. , 2005, The New England journal of medicine.

[78]  S. Hanauer,et al.  Budesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trial , 2005, Alimentary pharmacology & therapeutics.

[79]  S. Hanauer,et al.  A randomized, double‐blind, placebo‐controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, in patients with corticosteroid‐dependent Crohn's disease , 2005 .

[80]  A. Innes,et al.  Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study , 2004, Alimentary pharmacology & therapeutics.

[81]  M. Neurath,et al.  Anti-interleukin-12 antibody for active Crohn's disease. , 2004, The New England journal of medicine.

[82]  P. Rutgeerts,et al.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.

[83]  G. Radford-Smith,et al.  CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial , 2004, Gut.

[84]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[85]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[86]  Subrata Ghosh,et al.  Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.

[87]  S. Hanauer,et al.  Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States , 2002, American Journal of Gastroenterology.

[88]  B. Sands,et al.  Randomized, controlled trial of recombinant human interleukin‐11 in patients with active Crohn's disease , 2002, Alimentary pharmacology & therapeutics.

[89]  A. Zinsmeister,et al.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.

[90]  P. Rutgeerts,et al.  Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo‐controlled, double‐blind, multi‐centre clinical trial in active Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.

[91]  R. Pounder,et al.  A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's disease , 2001 .

[92]  S. Targan,et al.  An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. , 2001, Gastroenterology.

[93]  A. Forbes,et al.  Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn's disease , 2001 .

[94]  P. Rutgeerts,et al.  Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease , 2001, Gut.

[95]  P. Rutgeerts,et al.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease , 2000 .

[96]  P. Rutgeerts,et al.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. , 2000, Gastroenterology.

[97]  G. Greenberg,et al.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. , 2000, The New England journal of medicine.

[98]  W. Petritsch,et al.  Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. , 2000, Gastroenterology.

[99]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[100]  S. Targan,et al.  Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. , 1999, Gastroenterology.

[101]  A. Buchman,et al.  Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. , 1999, Gastroenterology.

[102]  G. D'Haens,et al.  Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. , 1999, Gastroenterology.

[103]  D. Jewell,et al.  Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. , 1999, Gastroenterology.

[104]  C. Bennett,et al.  A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. , 1998, Gastroenterology.

[105]  K. Ewe,et al.  Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease , 1998 .

[106]  Doe,et al.  Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month study , 1998, Alimentary pharmacology & therapeutics.

[107]  A. Lavy,et al.  Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. , 1997, The American journal of gastroenterology.

[108]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[109]  A. Prada,et al.  Controlled trial of oral 5‐aminosalicylic acid for the prevention of early relapse in Crohn's disease , 1997, Alimentary pharmacology & therapeutics.

[110]  C. Elson,et al.  Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. , 1997, Gastroenterology.

[111]  R. Fedorak,et al.  A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. , 1997, Gastroenterology.

[112]  M. Kamm,et al.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease , 1997, The Lancet.

[113]  J. Belaiche,et al.  Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. , 1996, Gastroenterology.

[114]  M. Vatn,et al.  Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease , 1995, Alimentary pharmacology & therapeutics.

[115]  M. Gerig,et al.  A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.

[116]  R. Modigliani,et al.  European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. , 1995, Gastroenterology.

[117]  Loyd,et al.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.

[118]  M. Scribano,et al.  Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. , 1995, Gastroenterology.

[119]  A. Zinsmeister,et al.  A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. , 1994, Journal of clinical gastroenterology.

[120]  G. Greenberg,et al.  Oral Budesonide for Active Crohn's Disease , 1994 .

[121]  A. Laupacis,et al.  Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. , 1994, The New England journal of medicine.

[122]  D. Jewell,et al.  Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial , 1994 .

[123]  G. Hommel,et al.  Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. , 1993, Gastroenterology.

[124]  S. Hanauer,et al.  Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. , 1993, Gastroenterology.

[125]  R. Modigliani,et al.  Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) , 1993, Gastroenterology.

[126]  C. Prantera,et al.  Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease , 1992 .

[127]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[128]  S N Rasmussen,et al.  A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. , 1989, The New England journal of medicine.

[129]  Province,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.

[130]  G. Guyatt,et al.  A new measure of health status for clinical trials in inflammatory bowel disease. , 1989, Gastroenterology.

[131]  K. Ewe,et al.  European cooperative Crohn's disease study (ECCDS) : Results of drug treatment , 1984 .

[132]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[133]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.

[134]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[135]  S. Vermeire,et al.  Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's disease who are antitumour necrosis factor inadequate responders , 2016 .

[136]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[137]  G. D'Haens,et al.  Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. , 2016, The Cochrane database of systematic reviews.

[138]  E. Louis,et al.  Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. , 2015, Gastroenterology.

[139]  P. Rutgeerts,et al.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[140]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[141]  Holger J. Schünemann,et al.  Health and Quality of Life Outcomes , 2006 .

[142]  S. Hanauer,et al.  A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. , 2005, Alimentary pharmacology & therapeutics.

[143]  A. Thorson.  Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease , 2005 .

[144]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[145]  G. Greenberg,et al.  Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. , 1996, Gastroenterology.

[146]  C. Herfarth,et al.  Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. , 1989, Digestion.

[147]  R. Baker,et al.  A controlled trial of disodium cromoglycate in the treatment of Crohn's disease. , 1980, Digestion.

[148]  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .